Denis DELVAL is appointed CEO of LFB SA
December 21, 2017
READ MORE >
UK launches FibCLOT®▼, LFB’s human fibrinogen concentrate
March 1, 2017
READ MORE >
2017 Rare Disease Day: LFB’s Commitment in the Field of Rare Diseases
February 28, 2017
READ MORE >
LFB S.A. announced today the acceptance by U.S. Food and Drug Administration of the filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)
January 6, 2017
READ MORE >
